CompletedPhase 2NCT00283712
Use of Infliximab for the Treatment of Pemphigus Vulgaris
Studying Pemphigus vulgaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Russell P. Hall, MDDivision of Dermatology, Duke University Medical Center
- Intervention
- Infliximab(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2011
Study locations (4)
- Norris Cancer Center, University of Southern California, Los Angeles, California, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
Autoimmunity Centers of Excellence
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00283712 on ClinicalTrials.govOther trials for Pemphigus vulgaris
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07384221Periodontal Status and Disease Severity in Pemphigus Vulgaris PatientsSaglik Bilimleri Universitesi
- RECRUITINGPHASE1, PHASE2NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Cabaletta Bio
- RECRUITINGNCT02753777Autoimmune Blistering Diseases StudyUniversity of Pennsylvania